Jade Biosciences, Inc.
For the period ended Jun 30, 2026. Filed Aug 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 10, 2026
JBIO$16.40+5.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands, except share amounts)
| June 30,2026 | December 31,2025 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $107,250 | $88,438 |
| Investments | 353,955 | 247,720 |
| Prepaid expenses and other current assets | 10,046 | 12,658 |
| Total current assets | 471,251 | 348,816 |
| Property and equipment, net | 144 | 170 |
| Operating lease right-of-use asset | 649 | 726 |
| Other assets | 69 | 69 |
| Total assets | $472,113 | $349,781 |
| Liabilities and Stockholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | 6,579 | 2,151 |
| Accrued expenses and other current liabilities | 14,922 | 9,419 |
| Related party accrued expenses and other current liabilities | 299 | 4,969 |
| Warrant liability, related party | 9,770 | — |
| Total current liabilities | 31,570 | 16,539 |
| Long-term liabilities: | ||
| Long-term lease liability | 628 | 724 |
| Total liabilities | 32,198 | 17,263 |
| Commitments and contingencies (Note 12) | ||
| Stockholders’ equity: | ||
| Series A non-voting convertible preferred stock, $0.0001 par value; 12,622 shares authorized as of both June 30, 2026 and December 31, 2025; 12,622 shares issued and outstanding as of both June 30, 2026 and December 31, 2025 | 2 | 2 |
| Common stock, $0.0001 par value; 300,000,000 shares authorized as of June 30, 2026 and December 31, 2025, respectively; 63,556,065 and 49,316,287 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 6 | 5 |
| Additional paid-in capital | 711,089 | 506,771 |
| Accumulated other comprehensive (loss) income | (660) | 129 |
| Accumulated deficit | (270,522) | (174,389) |
| Total stockholders’ equity | 439,915 | 332,518 |
| Total liabilities and stockholders' equity | $472,113 | $349,781 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.